Researchers have narrowed down the malaria proteins and disease-fighting antibodies that could be used to develop a vaccine against the most severe forms of malaria.
BioVision's ToxOut Protein A (Sepharose) and ToxOut Protein G (Sepharose) Antibody Purification Kits enable the purification of monoclonal and polyclonal antibodies.
A new study points to the need for better antibody validation and outlines a process that other labs can use to make sure the antibodies they work with function properly.
Merck has introduced its ADC Express services for the rapid production of ADCs, designed to reduce the time needed to produce development-grade constructs for target molecule identification.
St John's Laboratory has a selection of loading controls for western blot and other applications that cover a wide range of molecular weight proteins suitable for users' experiments.
GeneTex offers an extensive collection of high-quality antibodies for research of the central nervous system.
AdipoGen develops recombinant monoclonal antibodies (RecMAbs) without the use of animals. The antibodies are created using an in vitro technology, antibody phage display — an alternative to the hybridoma technology that circumvents the limitations of the immune system.
Absolute Antibody's murine bispecific reagents enable researchers and drug developers to more easily evaluate potential bispecific combinations in mouse models.
The Anti-Alpaca secondary antibody product line targets the IgG repertoire of camelid immunoglobulins, including whole molecule, subclass and VHH domain specificities. They are raised against alpaca and cross-react with llama.
Scientists have developed a new antibody technology that combines the advantages of antibody-based therapies with the convenience of oral drug administration.
Leica Biosystems' PD-L1 BOND antibody is designed for use on their fully automated BOND IHC and ISH staining platform.
The scientific community is currently facing a reproducibility crisis. Over 70% of researchers are failing to reproduce published experiments.
Biotechnology company IONTAS has announced a panel of human antibodies that neutralise elements of black mamba snake toxin in an in vivo model.
Bio-Rad Laboratories has launched a range of recombinant monoclonal anti-ranibizumab antibodies that are highly specific for the monoclonal antibody drug ranibizumab (Lucentis) or the complex of ranibizumab with its target, vascular endothelial growth factor A (VEGF-A).
Thermo Fisher Scientific will utilise BenchSci's machine learning platform to mine antibody data published in peer-reviewed scientific journals.